Implementation of a Screening Process for Chemotherapy-Induced Peripheral Neuropathy

Bindu Pradeep, DNP, APRN, FNP-BC

<u>DNP Project Advisor: Dorothie Durosier Mertilus, Ph.D., DNP, APRN, AGNP-C</u>

BACKGROUND

- Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of most cancer-treating drugs.
- CIPN can cause balance and gait deficits, which may result in a significant increase in fall incidence.
- ❖ Exercise interventions are beneficial for reducing CIPN symptoms and improving lower extremity strength and balance. ³
- The outpatient clinic needs a standardized approach to screening cancer patients for CIPN.

PROJECT PURPOSE

Purpose: To early identify CIPN to reduce fall rates in an outpatient clinic


Aim: To implement a screening process for CIPN in an outpatient clinic to improve the rate of referrals to a Gait and Balance Clinic (GBC).

Clinical Question: In patients with cancer aged 65 years and older, does the implementation of a screening process for chemotherapy-induced peripheral neuropathy compared to no screening increase the rate of referrals to a GBC over a three-month period?

MODEL/NURSING THEORY

Reevaluate the data and make changes to ensure it accurately reflects the needs of the senior adult population

Determine the effectiveness of the CPIN screening process in increasing the rate of referrals to a GBC



Determine whether the standard CIPN screening process increases the number of people referred to a GBC

Implement the CIPN screening process over twelve weeks

METHODS

Participants: 610 patients with cancer aged 65 years and older undergoing active cancer treatment

Setting: A Senior Adult Clinic at Cancer Center in West Central Florida


Outcomes: Rates of referrals to the GBC, CIPN screening, and CIPN-specific education completed


Validated Source: Electronic medical record (EMR)


Intervention and Data Collection: Implementation of the CIPN screening process over 12 weeks

- Ask 2 screening questions at every visit
- Educate patients if CIPN score = 1-10
- Refer to GBC if CIPN score ≥ 7
- Collect pre- and post-implementation data


RESULTS







Reason for Not Being Referred to GBC



		Standard Deviation	Minimum	Maximum
Age	76.44	6.56	40	99
CIPN Score	1.11	2.40	0	10

Education given 120 100 80 60 40 20 No Yes

CIPN Education Received			
	Frequency	percent	
NO	10	1.1	
Yes	111	12.2	
Total	121	13.3	

DISCUSSION

- The screening rate was 58.3%.
- ❖ There was no significant improvement in the rate of referrals to the GBC.
- ❖ The screening process improved the rate of CIPN education received by patients.
- The screening questions assisted in the identification of patients at risk for CIPN; however, they did not capture all aspects of peripheral neuropathy.

Limitations

- Providers' perceptions
- Staffing
- The screening process included only 2 questions from the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) questionnaire.⁴
- Each screening question was self-reported and could have been influenced, either consciously or unconsciously, by social desirability or response bias.

IMPLICATIONS FOR ADVANCED PRACTICE NURSING

- Early detection of CIPN is crucial in developing interventions to prevent or reduce CIPN-related deterioration.⁶
- Regular CIPN assessment helps to avoid further impairments, especially if patients already have a declining functional capacity.⁶
- Early screening for CIPN can help decrease fall risk and other balance problems in cancer patients.⁶
- Exercise interventions are beneficial for reducing CIPN symptoms and improving lower extremity strength and balance.

SUSTAINABILITY

- Education about the importance of screening for CIPN will be integrated into the annual mandatory training.
- Nurse champions will be designated to ensure staff adherence and commitment to improving the screening process.

REFERENCES



